INTRODUCTION
Dr: John P. Hayslett: The clinical features of lupus nephropathy will be illustrated by a patient who has been under my care for the past eight years. This patient has graciously accepted an invitation to participate in this conference to comment on experiences with her illness and treatment. Dr. Hugh Carey, Department of Pathology, will discuss the histopathological findings observed in the series of renal biopsies performed to determine the course of treatment.
CASE PRESENTATION The clinical course began in 1981, as shown in Figure 1 , when she developed a facial rash, buccal ulcerations, arthralgias and arthritis and low-grade fever, and the diagnosis of systemic lupus erythematosus was made. She was treated with prednisone and plaquenil and achieved some symptomatic relief, although at a dose of prednisone above 15 mg/day she experienced substantial side effects in the form of impairment of recent memory, a reduction in attention span and increased fatigability.
Proteinuria was first observed in March 1987, when renal function was normal. Subsequently she experienced a clinical flare with hair loss, facial rash, recurrence of buccal ulcerations and low-grade fever. In the fall of 1987, a renal biopsy was performed at another institution. On the basis of the renal biopsy, the dose of prednisone was increased to about 30 mg/day, which caused considerable side effects. I initially met the patient and her husband in January of 1988 when they sought my opinion about the prospect of pregnancy. On physical examination she had an erythematous rash on her face and over her sternum and petechiae on her hard palate. There was a livido-reticular reaction on the fingers and hands, consistent with peripheral vasospasm. She also had dependent pitting edema and appeared to be chronically ill. Because an assessment of the activity of systemic lupus erythematosus was an important factor in her candidacy for pregnancy, we retrieved the renal biopsy that was performed at that other institution for review. Dr. Carey, will you please show the first renal biopsy?
Dr. Hugh Carey:
The histopathology of lupus nephritis is predominantly the study of glomerular immune complex disease, and I will limit the focus of discussion to that, although tubulo-interstitial and vascular lesions frequently play a significant role.
I will briefly review normal glomerular histology. The glomerulus shown in Figure 2 is enclosed within Bowman's capsule and consists of a delicate bundle of capillary loops supported by a dynamic cellular structure, the mesangium. Endogenous glomerular cells include the mesangial cell, endothelial cell, visceral epithelial cell or podocyte and the parietal epithelial cell.
By electron microscopy ( Figure 3 ), one can see a discrete section of a normal glomerulus with mesangium, associated capillary loops and Bowman's space. The mesangium contains the mesangial cell and associated modestly electron-dense mesangial matrix material. The capillary loops consist of an inner, modified, fenestrated endothelium, a trilaminar basement membrane and the outer interdigitating foot processes arising from the podocytes. Immune complexes may form either within the mesangium, within the subepithelial space between foot processes and the basement membrane or within the Hayslett: At this time, the patient had active disease on physical examination and by history, as well as proteinuria (2.5 gm/day) and hypoalbuminemia; dependent edema was secondary to nephrotic syndrome. The renal biopsy performed two months earlier showed a Class IV lesion that reflected active lupus nephritis. I suggested that pregnancy should not be attempted at that time because observational studies indicated that the likelihood of a successful pregnancy is much greater if undertaken at a time when disease is inactive. I also indicated that the initial interpretation of the renal biopsy underestimated the severity of her renal disease and suggested that she would benefit from immunosuppressive therapy to suppress the injury reaction.
Our approach to the treatment of acute lupus nephritis, based on studies that will be discussed subsequently, involved the administration of an immunosuppressive drug, and a glucocorticoid in an amount sufficient to suppress extrarenal manifestations of systemic lupus erythematosus, for at least two years. In addition, we advocated re-examination of renal histopathology by biopsy after two years to determine the effect of therapy on the pattern on renal injury because measures of renal function and serological tests are not precise markers of the response to treatment. The patient was therefore treated with azathioprine, 1 mg/kg body weight, and prednisone was continued in a dose of about 15 mg/day. Azathioprine was advantageous in this patient because it does not induce infertility, as alkalating drugs such as cyclophosphamide are likely to do.
During the first 12 months of treatment, the extrarenal manifestations of disease resolved, and, as shown by Figure 1 , protein excretion was reduced from nephrotic levels to 500 mg/day. Apparently because of clinical improvement, her primary physician discontinued azathioprine. Five months later, as shown in Figure 1 , she experienced a severe flare and a recurrence of nephrotic syndrome.
Although the initial course suggested that azathioprine had substantially suppressed the acute inflammatory reaction in the kidney, this potential response to treatment was not documented by renal biopsy. It was not possible, therefore, to distinguish between a recurrence of a severe inflammatory reaction and a transformation from the lesion seen on the first biopsy to a membranous lesion (Class V). Because a distinction between these two possibilities would influence our therapeutic decision, I recommended repeating the renal biopsy.
D)r Carey:
By light microscopy, there was significant mesangial widening, markedly thickened capillary loops and diffuse cellular proliferation. Leukocytes were seen within capillary loops. There was focal necrosis. By electron microscopy, there was mesangial expansion with mesangialization of the basement membrane, and abundant subepithelial and subendothelial deposits were present. This lesion, therefore, represented a Class IV diffuse proliferative glomerulonephritis.
Dr Hayslett: It seemed likely, as noted, that the patient had responded to azathioprine and that relapse of both renal and non-renal aspects of disease occurred because of premature termination of the immunosuppressive agent. We therefore reinstituted azathioprine in the same dose as before. Although the non-renal symptoms resolved after several months of treatment, heavy proteinuria persisted. At this time, I was concerned that she was refractory to azathioprine and, if so, that progressive damage to renal parenchyma could lead to renal insufficiency. I decided to examine the renal histopathology ten months after starting the second course of azathioprine. Dr. Carey, will you discuss the results of this biopsy?
Dr Carey:
At this time, there was significant proliferation in the majority of glomeruli. There was also small cellular crescent formation indicative of necrosis. Capillary loops were markedly thickened. By electron microscopy, there were diffuse large subepithelial deposits, as seen in membranous nephropathy; but focally, within the subendothelial space, there was persistence of significant subendothelial deposits. So again, we have a Class IV diffuse proliferative glomerulonephritis with some focal necrosis, although severity was reduced compared to the previous biopsy. There was an increasing background of subepithelial deposits or membranous transformation. Dr. Hayslett: The primary goal of treatment was suppression of the acute inflammatory reaction in the glomerulus and resolution of subendothelial deposits of immune complexes. Since this aim was not achieved after nearly a year of therapy with azathioprine, it seemed reasonable to change the immunosuppressive agent. Then, as well as now, the only alternative drug was cyclophosphamide. A recent report in 1986 from a National Institutes of Health study suggested that intermittent intravenous therapy was at least as good as daily oral treatment [1] . I therefore offered the patient a choice of either mode of administration, and she chose the intravenous regimen. Treatment was continued for two years in a dose of 500 mg/M2 at monthly intervals for the first twelve months, and thereafter, at intervals of three months.
By the end of the first year of treatment, urine protein excretion was reduced to about 500 mg/day and reached lower levels in the second year. Extrarenal manifestations of systemic lupus erythematosus had completely resolved. We performed renal biopsies after 12 months to determine whether the injury pattern had improved and again at the end of therapy to establish a baseline evaluation before terminating cyclophosphamide. Dr This is a silver stain of a typical glomerulus after one year of cyclophosphamide therapy (1991) (Figure 7 ). Capillary loops were diffusely thickened. Cellularity is moderately increased but there is no evidence of an inflammatory infiltrate or necrosis. By electron microscopy ( Figure 8) , punctuated along the subepithelial space are numerous large subepithelial deposits; no subendothelial deposits were present. Transformation to a Class V membranous lesion was complete. Another biopsy, a year later, again showed mesangial widening by silver stain; cellularity was normal, the basement membrane was still relatively thickened, and, by electron microscopy, there were large subepithelial electrondense deposits. The patient had a persistent Class V membranous lupus lesion.
Dr. Hayslett:
At this time, we had biopsy evidence that the acute inflammatory reaction had resolved and that peripheral subendothelial deposits had disappeared. The proliferative glomerulonephritis initially observed had transformed to a membranous nephropathy, with only negligible amounts of interstitial scarring. Renal function was normal and protein excretion was near normal. We discontinued cyclophosphamide therapy, but continued prednisone at a low dose of 10 mg/day for a year and a half. She has received no therapy for the past fifteen months, and measures of renal function have remained normal. We continued to monitor laboratory parameters at three-month intervals for possible signs of recurrence. I will start this discussion with the question: can women with systemic lupus erythematosus safely carry pregnancy to a successful outcome? Systemic lupus erythematosus is a disease of young women during reproductive years with a peak appearance at age 18 to 19. The issue of whether it is safe to attempt pregnancy is a very important issue for this group of patients. It was previously thought that pregnancy and systemic lupus erythematosus did not mix, because the outcome of pregnancy was an ominous one. Women with this disease were, therefore, advised against pregnancy, and if they became pregnant, were advised to terminate. During the last fifteen years, however, there have been several studies which indicate that the outcome depends on the activity of disease at the time that~~~~~~~~~~Y N _11! 1Va Figure 8 . Electron micrograph of the same renal biopsy shown by Figure 7 , demonstrating a typical membranous pattern with subepithelial deposits. pregnancy is initiated [2] . In women who are in complete clinical remission for six months to a year at the time of conception, the incidence of flares is reported to be low and usually mild, and usually subside after delivery. In contrast, when pregnancy began with active disease, the incidence of flares was much higher; these were usually more severe and sometimes resulted in irreversible organ death. Pregnancy outcome correlated with maternal disease activity: that is, when the maternal disease was quiescent there was a high fetal survival, which averaged 90 to 100 percent in the four series where data were available for this analysis. However, in pregnancies in which there was active maternal disease, fetal survival was reduced to about 70 percent. A favorable outcome included women who had initially had severe renal involvement, as in this woman's case, and even renal insufficiency, if there was no clinical evidence of systemic lupus erythematosus activity immediately prior to the onset of pregnancy. In this case, the issue of having children was resolved because she and her husband successfully and happily adopted two children.
When this patient sought advice about the possibility of a successful pregnancy outcome, she exhibited active systemic disease and a diffuse proliferative glomerulonephritis. My answer to her inquiry, as well for her own well-being, depended on our ability to control her active disease and reverse her severe nephropathy that had resisted acceptable levels of glucocorticoids. I will focus the remaining portion of the discussion on three questions: 1) Does the risk for renal failure correlate with specific types of renal injury? 2) Can the pattern of renal injury be altered by drug therapy? and, if so, 3) What type of drug treatment appears to be most efficacious? In the 1960s, it was clear that the outcome of patients with lupus nephritis was predicted by the pattern of injury. Renal failure was most often associated with a diffuse proliferative glomerular nephritis, in contrast to other histopathological lesions. In the 1970s studies that analyzed renal biopsy material by electron microscopy showed that among patients with a proliferative lesion, the presence of subendothelial electron-dense deposits was a singularly important harbinger for progressive disease and renal failure [3] .
A report from this institution in which intervention with an immunosuppressive agent was employed strengthened the association between the presence of subendothelial deposits in peripheral capillary loops and a poor renal outcome, and demonstrated that a severe renal lesion could be modified. In this analysis, 31 patients with a Class IV lesion were treated with azathioprine and low-dose prednisone [4] . A renal biopsy was performed before starting treatment and two years later. At the end of follow-up, which averaged 40 months, patients were classified as improved (normal serum creatinine and protein excretion), stable (the same but with low-grade proteinuria), or deteriorated (renal insufficiency and/or nephrotic syndrome). At the end of follow-up, nearly all patients in the improved/stable category who had a second biopsy exhibited either normal histology or a membranous pattern on the second renal biopsy, with complete resolution of subendothelial electron-dense deposits, as shown in Figure 9 . In contrast, one-third of the group were classified in the deteriorated category by clinical criteria, and all patients who had a second biopsy had persistent subendothelial deposits. The results of this series, therefore, showed that lupus nephropathy could be modified by treatment and highlighted the risk posed by subendothelial deposits for progressive renal disease.
Observational studies performed at Yale on a larger number of patients with lupus nephritis, by biopsy from 1967 to 1983, have subsequently been reported [5] . Eightyseven patients were analyzed. Nearly 80 percent had a Class III or IV lesion, and most were treated with a combination of azathioprine and low-dose prednisone. Follow-up averaged twelve years and renal and patient survivals are shown in Figure 10 . Renal survival was 90 percent and patient survival was 77 percent. A poor renal outcome was predicted by renal insufficiency and heavy proteinuria at time of biopsy, and by the histopathological findings of an active proliferative lesion, subendothelial deposits and evidence of tubulointerstitial inflammation and scarring. Non-renal deaths were predicted by co-morbid disease, mainly atherosclerotic disease and hypertension and older age. Delay in initiating immunosuppressive therapy was associated with a higher incidence of renal failure than when therapy began soon after the appearance of clinical renal disease [6] . A second renal biopsy was performed in 42 of these patients [7] . As in the earlier study, the second biopsy showed a decrease in active inflammation and an increase in parenchymal scarring, a decrease in subendothelial deposits and an increase in membranous transformation. This analysis was consistent with the notion that suppression of the active renal lesion with clearing of subendothelial deposits was associated with preserved renal function. Similar results were reported from Europe by Dr. Ponticelli in a series of 43 patients with Class III or IV lupus nephropathy [8] . These patients were treated with pulse steroid treatment monthly for three months and then with low-dose steroids. Thirty-one of these patients also received oral immunosuppressive agents, either azathioprine or cyclophosphamide. At Figure 11 . Summary data of NIH prospective trials of treatment of lupus nephritis [1] .
viduals. Together with our experience this study indicates that renal failure can be prevented even in patients with the more severe forms of lupus nephropathy with therapy that usually combines an immunosuppressive agent with prednisone. Besides these observational studies, it is important to discuss the prospective study performed by the Rheumatology Section at the National Institutes of Health [1] . This study has had a profound effect worldwide on the treatment of lupus nephritis. A trial was begun in 1969 and closed in 1976 to compare oral prednisone with the oral administration of azathioprine or cyclophosphamide. Patients were randomized to one of the three groups if they met entry criteria for the study. Four years later, a second trial was initiated, which compared oral prednisone to two other experimental groups, one with both azathioprine and cyclophosphamide administered orally and another with cyclophosphamide given intravenously at three-month intervals, The second study was closed in 1981. The results of both trials were reported in 1986 [1] and this Figure 11 summarizes the results by showing the incidence of renal failure by cumulative survival analysis, with some patients followed for as long as 160 months. Regarding the prednisone control group, Group 1 includes all patients treated since 1969, apparently including patients entered after the first study was closed in 1976. Group IA indicates the control group for the second trial which analyzed combined azathioprine and cyclophosphamide (AZCY)C and intravenous cyclophosphamide (IVCY). Most patients had proliferative glomerulonephritis by light microscopy; biopsy material was not analyzed by electron microscopy. The risk for renal failure was similar for patients treated with oral azathioprine, oral cyclophosphamide and prednisone (Group 1). Regarding the second trial there was no difference between the experimental groups AZCY and IVC, and the concurrent Group IA. In a subsequent study, published in 1991, when followup was extended to 220 months, the AZCY and IVCY groups were said to differ significantly from control [9] . However, in that report, the control appeared to include historical controls enrolled before the experimental groups were initiated, as well as concurrent controls. On the basis of these data, the investigators conclude that IVCY was superior to other methods in the treatment of lupus nephropathy.
Although prospective by design, I believe it is questionable whether the study is superior to observational studies regarding the efficacy of different treatment regimens. Hopefully, others in this room can be induced to look critically at the design and interpretation of these experimental trials. To me it appears that the small number of patients in each group, about twenty, substantially reduces statistical power because of risk for random error, especially in a disease with a highly variable course. It should be noted that patients were not initially randomized for apparent risk factors for poor outcome. In contrast to the usual procedure for scientific study, a clear plan for the duration of therapeutic regiments and/or end-point for final analysis has never been defined. Regarding analysis, I am concerned about comparing multiple experimental groups to a single control, the use of non-concurrent controls in analysis, and employment of sequential analyses of the same populations, presumably well beyond time of adherence to specific treatment protocols. For these reasons, therefore, I do not find this study compelling in selecting treatment for patients with lupus nephropathy.
A review of medical reports and analysis of data, however, are only part of the discussion of an illness; another part is how the illness affects the life of individual patients. I, therefore, welcome the comments of the patient whose course was described earlier.
Will you tell us about the symptoms you experienced when systemic lupus erythematosus first began? Before closing the discussion in this Grand Rounds, I would like to indicate that the clinical course of systemic lupus erythematosus is not necessarily as hectic as experienced by this patient or patients included in the reports that I have discussed. An interesting paper was reported from southern Sweden a few years ago on all patients who developed systemic lupus erythematosus between 1979 and 1986 in a defined population of 163,000 [10] . All patients were diagnosed and managed by one clinic with three physicians. The incidence of new cases was four per 100,000 adults per year. The cumulative organ system involvement is shown in Table 1 In summary, the outlook for patients with lupus nephritis is much better than reported in the past. Patient survival is near normal when adjusted for age, and survival of renal function is about eighty-five percent. Although not proven by scientific study, I believe that the better outcome in patients with diffuse proliferative glomerulonephritis is attributable, in large part, to the use of immunosuppressive drugs such as azathioprine and cyclophosphamide. Further, our experience and that of others suggest that treatment should be continued for at least two years and should aim to transform the pattern of renal injury to a more benign form. Renal biopsy is the only means to assess the effect of treatment. I also believe that there is a window of opportunity to achieve a favorable outcome because once significant irreversible damage occurs the action of drug treatment becomes limited. One can only hope that more specific and less toxic therapy will become available in the near future.
